Solvay S.A.
22.1.2021 08:31:56 CET | Globenewswire | Press release
Participation notification by Blackrock Inc.
Brussels, 22 January 2021, 08:30 CET - According to Belgian transparency legislation (Law of May 2, 2007), BlackRock Inc. (55 East 52nd Street, New York, NY, 10055, U.S.A.) recently sent to Solvay the following transparency notifications indicating that it crossed the threshold of 3%. Here is a summary of the moves:
| Date on which the threshold was crossed | Voting rights after the transaction | Equivalent financial instruments after the transaction | Total |
| January 18, 2021 | 2.84% | 0.18% | 3.01% |
| January 19, 2021 | 3.01% | 0.09% | 3.10% |
The latest notification, dated January 20, 2021, contains the following information:
- Reason for the notification: acquisition or disposal of voting securities or voting rights
- Notified by: BlackRock Inc. (55 East 52nd Street, New York, NY, 10055, U.S.A.)
- Date on which the threshold is crossed: January 19, 2021
- Threshold of direct voting rights crossed: 3% upwards
- Denominator: 105,876,416
- Additional information: The disclosure obligation arose due to voting rights attached to shares for BlackRock, Inc. going above 3%.
Transparency notifications and the full chain of controlled undertakings through which the holding is effectively held is available on the Investor Relations Section of Solvay's website.
Attachments
- Solvay_2021-01-18_Issuer_signed
- Solvay_2021-01-19_Issuer_signed
- 20210119_transparency declaration Blackrock-EN
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About Globenewswire
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Genmab A/S3.10.2026 21:40:00 CEST | Press release
Genmab Announces Rinatabart Sesutecan (Rina-S®) Phase 2 RAINFOL™-01 Results Demonstrated Durable and Clinically Meaningful Responses in Patients with Platinum-Resistant Ovarian Cancer
Chery Group3.10.2026 14:28:18 CEST | Press release
FREELANDER Marks a New Chapter at Its Global Brand Launch in Abu Dhabi
Chery Group3.10.2026 14:16:10 CEST | Press release
FREELANDER Sets Out Its International Roadmap with a Phased Expansion from the Middle East
Chery Auto3.10.2026 10:47:01 CEST | Press release
LEPAS Enters Romania: LEPAS L8 PHEV Officially Launches as First Flagship Store Opens
Novo Nordisk A/S2.10.2026 22:53:42 CEST | Press release
Novo provides update on the denecimig Biologics License Application (BLA) in the US
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
